Blood Cancer Program

Activities

Activities per year 2005 2016 2018 2019 2020 2021 2023 2024 2024

• 122 Other
• 62 Oral conference presentations and other invited talks
• 34 Membership of funding review panel
• 25 Publication peer-review
• 111 More
  • 22 Membership of committee
  • 18 Consumer Engagement
  • 17 Membership of network
  • 15 Organising a conference
  • 15 Invited Keynote and Plenary Presentations
  • 6 Participation in conference
  • 4 Consultancy and providing expertise
  • 4 Editorial Board Role
  • 4 Examination
  • 3 Membership of board
  • 2 Participation in workshop, seminar, course
  • 1 Organising a workshop, seminar, course

Activities per year

Search results

• Gut Dysbiosis may adversely impact treatment responses with TKIs in ABL-rearranged high-risk B-ALL

  Page, E. (Speaker)

  29 Oct 2024

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• Metabolic vulnerabilities of myeloid neoplasm and autoimmune disease.

  Hiwase, D. (Speaker)

  15 Oct 2024 → 17 Oct 2024

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• MDS Recent Updates

  Hiwase, D. (Invited speaker)

  17 Nov 2024 → 18 Nov 2024

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• New Directions in Leukaemia Research (NDLR)

  Eadie, L. (Speaker)

  4 Mar 2024 → 6 Mar 2024

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• When Frontline Therapy Fails

  Yeung, D. (Invited speaker)

  17 Oct 2024 → 18 Oct 2024

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• CML Beyond Chronic Phase

  Shanmuganathan, N. (Invited speaker)

  17 Oct 2024 → 18 Oct 2024

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• ALL-IMMUNE Study Update

  White, D. (Keynote speaker)

  13 Dec 2024

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• ALL-IMMUNE Study Update

  White, D. (Keynote speaker)

  9 Sept 2024

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• Mesenchymal stromal cells from patients with therapy-related myeloid neoplasms exhibit a unique metabolic phenotype with defective adipocyte differentiation.

  Kutyna, M. (Speaker)

  15 May 2024 → 17 May 2024

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• Ph+ ALL Management - 2024

  Yeung, D. (Invited speaker)

  17 Oct 2024 → 18 Oct 2024

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• CMML Diagnostics and Therapy

  Thomas, D. (Invited speaker)

  17 Oct 2024 → 18 Oct 2024

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• Treatment Free Remission: MRD Studies.

  Pagani, I. (Invited speaker)

  17 Oct 2024 → 18 Oct 2024

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• ALL-IMMUNE Study Update

  White, D. (Keynote speaker)

  24 Jun 2024

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• ALL-IMMUNE Study Update

  White, D. (Keynote speaker)

  10 Dec 2024

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• SAHMRI Precision Cancer Medicine Theme International Women’s Day Seminar

  Eadie, L. (Speaker)

  8 Mar 2023

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• SAHMRI Research Showcase

  Eadie, L. (Speaker)

  15 Nov 2022 → 16 Nov 2022

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• Blood 2022

  Eadie, L. (Speaker)

  11 Sept 2022 → 14 Sept 2022

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• Mitochondrial DNA mutations are associated with reduced OXPHOS and response to imatinib in chronic myeloid leukaemia patients. Ilaria S Pagani, Chung H Kok, Phuong Dang, Kelly Lim, Verity A Saunders, Madeleine Hughes, David T Yeung, Daniel Thomas, Timothy P Hughes, David M Ross.

  Pagani, I. (Speaker)

  2021 → …

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• MEK inhibitors as a targeted therapy approach to overcome resistance in Ph+ ALL cell line with PTPN11 mutations. Poudel G, Asari K, Yeung DT, White DL, Hughes TP, Pagani IS.

  Pagani, I. (Speaker)

  2021

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• John Curtin School of Medical Research Seminar

  White, D. (Invited speaker)

  Jul 2021

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• The impact of glutamine starvation on survival and proliferation in K562 sensitive and imatinib resistant chronic myeloid leukemia cell lines. Hughes M, Saunders V, Hughes TP, Pagani IS.

  Pagani, I. (Speaker)

  2021

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• Invited Speaker: RCPA: Introductory Short Course in Genetics and Molecular Pathology

  White, D. (Invited speaker)

  Nov 2021

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• Box Hill Haematology scientific meeting ‘EiNSTEIN’

  White, D. (Invited speaker)

  Apr 2021

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• Interrogating the genomic consequences of Ph-like acute lymphoblastic leukaemia in adolescents using single cell mRNAseq.

  Heatley, S. (Speaker)

  11 Mar 2021 → 12 Mar 2021

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• Distinct differences between diagnosis and relapse of Ph-like acute lymphoblastic leukaemia in adolescents are revealed by single cell mRNAseq

  Heatley, S. (Speaker)

  20 Sept 2021 → 23 Sept 2021

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• In-vitro modelling of relapsed, refractory acute lymphoblastic leukaemia from a child with neurofibromatosis.

  Heatley, S. (Speaker)

  20 Sept 2021 → 23 Sept 2021

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• Australian and New Zealand Children’s Haematology/Oncology Group (ANZCHOG) Scientific Meeting

  Eadie, L. (Speaker)

  23 Jun 2021 → 25 Jun 2021

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• Mitochondrial DNA mutations are associated with response to imatinib in chronic myeloid leukaemia patients. Pagani IS, Kok CH, Dang P, Lim K, Saunders VA, Hughes M, Kutyna MM, Hiwase DK, Yeung DT, Thomas D, Hughes TP, Ross DM.

  Pagani, I. (Speaker)

  2021 → …

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• Drug Discovery and Development SA Symposium

  White, D. (Invited speaker)

  Mar 2021

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• Interrogating the genomic consequences of Ph-like acute lymphoblastic leukaemia in adolescents using single cell mRNAseq

  Heatley, S. (Speaker)

  22 Jun 2021 → 25 Jun 2021

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• Understanding the mechanisms of imatinib resistance in a Ph+ acute lymphoblastic leukaemia cell line. Poudel G, Yeung DT, White DL, Hughes TP, Pagani IS.

  Pagani, I. (Speaker)

  2020

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• ABMC Research Mini-Review: Therapeutic triage and risk stratification in leukaemia: the important role of genomics

  White, D. (Invited speaker)

  Sept 2020

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• ALLG: the importance of mRNA Seq in diagnosis, risk stratification and therapeutic triage.

  White, D. (Invited speaker)

  Nov 2020

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• The rate of BCR-ABL1 decline after TKI commencement is a strong predictor of sustained treatment free remission. Shanmuganathan N, Branford S, Pagani IS, Ross, DM, Park S, Yong ASM, Braley J, Altamura H, Hiwase DK, Yeung DT, Kim D-W and Hughes TP.

  Pagani, I. (Speaker)

  2020

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• Kiwanis Childhood Cancer Symposium

  White, D. (Invited speaker)

  Sept 2020

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• Kiwanis Club of Waverley

  White, D. (Invited speaker)

  Aug 2020

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• ALLG: the importance of mRNA Seq in diagnosis, risk stratification and therapeutic triage.

  White, D. (Invited speaker)

  Nov 2019

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• In search of the residual leukaemic clone in chronic myeloid leukaemia patients in treatment-free remission. Pagani IS, Dang P, Saunders VA, Grose R, Shanmuganathan N, Carne L, Rwodzi Z, Watts S, McLean J, Braley J, Yeung DT, Branford S, Yong ASM, White DL, Hughes TP, Ross DM.

  Pagani, I. (Speaker)

  2019

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• Lineage of residual BCR-ABL1-positive cells in chronic myeloid leukaemia patients in treatment-free remission. Pagani IS, Dang P, Saunders VA, Grose R, Shanmuganathan N, Carne L, Rwodzi Z, Watts SM, McLean J, Braley J, Altamura H, Yeung DT, Branford S, Yong ASM, White DL, Hughes TP, Ross DM.

  Pagani, I. (Speaker)

  2019

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• Lineage of Residual Disease in Patients with Chronic Myeloid Leukaemia in Treatment-free Remission

  Pagani, I. (Speaker)

  2019

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• ANZCHOG ASM 2019

  White, D. (Speaker)

  Nov 2019

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• Albert-Ludwigs-Universitat Freiburg. Institute for MolecularMedicine. “Cancer and Development” meeting.

  White, D. (Speaker)

  2018

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• International Berlin Frankfurt Munster (BFM) Scientific Meeting

  White, D. (Speaker)

  2018

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• Exploring the genomic diversity of adult and AYA high-risk B-ALL cases by mRNA sequencing.

  Heatley, S. (Speaker)

  14 Jun 2018 → 18 Jun 2018

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• Exploring the genomic diversity of adult and AYA cases with high-risk B-ALL by mRNA sequencing

  Heatley, S. (Speaker)

  25 Mar 2018 → 28 Mar 2018

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• Lineage of Residual Leukaemic Cells following TKI-treatment in Chronic Myeloid Leukaemia 

  Pagani, I. (Speaker)

  2018

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• Invited Session Chair and Facilitator: iCMLf meeting Miami

  White, D. (Speaker)

  2018

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• Comparison of genomic and reverse transcriptase Q-PCR for the monitoring of first-line imatinib treatment: an ALLG CML9 sub-study. Pagani IS, Dang P, Kommers IO, Goyne J, Saunders V, Prime JA, White DL, Branford S, Hughes TP, Ross DM.

  Pagani, I. (Speaker)

  2017

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• The Landscape of Mitochondrial DNA Mutations in Chronic Myeloid Leukaemia and Clinical Implications

  Pagani, I. (Speaker)

  2016

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks

• ASMR Annual Scientific Meeting

  Eadie, L. (Speaker)

  8 Jun 2016

  Activity: Invited talks and oral presentations › Oral conference presentations and other invited talks